Our findings demonstrate that the stereotaxic injection of CRISPR/CasRx into the striatum of HD 140Q-KI mice, both in the early and late stages of the disease, effectively downregulates the expression of HTT mRNA and alleviates the neuropathology associated with gliosis. This evidence concerns the gene HTT and Huntington disease.